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Long-term follow-up of Canadian clinical trial of antilympho-
cyte globulin in renal transplantation. C. F. D. Ackman, H. E.
Taylor, and R. S. Schual. Department of Urology, McGill Uni-
versity, The Montreal General Hospital, Montreal, Quebec. In
1976, the results of a multicenter randomized clinical trial of anti-
lymphocyte globulin (ALG), conducted among patients who had
undergone cadaver renal transplant, was reported with a follow-
up of 1 year minimum. One hundred seventy-nine patients, of
whom 92 were treated conventionally and 87 were additionally
given ALG for 10 days, were included in the study funded by the
Medical Research Council. Less than half the number of acute
rejections and a reduction of prednisone utilization was noted.
At 1 year, the ALG group showed a 10% better graft survival.
This same group of patients has now been followed for a mini-
mum of 3 years and in some cases 5 years. Differences in creati-
nine levels, graft survival, prednisone utilization, and long-term
complications have been compared with the original study. Evi-
dence suggests that the early differential graft survival persists.
No significant immunologically oriented complications have
been noted.
Detection of antidonor antibody: Advantages of fibroblast target
cells. M. Aprile, P. Halloran, M. Robinette, and G. Haddad. Mt.
Sinai Hospital, Toronto, Ontario. Donor-specific alloantibody
was monitored in 36 kidney transplants for 3 months or more
posttransplant. Two 51Cr release assays were used: complement-
dependent lysis and antibody-dependent cell-mediated cyto-
toxicity. Fibroblast, lymphocyte, and lymphoblast target cells
were all tested whenever possible. Antibody was detected in on-
ly 3 of 20 patients who achieved good function (creatinine < 3 at
3 months), but in 12 of 16 patients who had an unfavorable out-
come (return to dialysis or creatinine > 5 at 3 months). The asso-
ciation of antifibroblast antibody with poor function was particu-
larly striking. In the 33 patients in whom donor fibroblasts were
tested, none of 19 with good function had detectable antibody,
whereas 9 of 14 with graft loss or poor function had detectable
antibody (x2 = 16.8, P < 0.0005). The association of anti-
fibroblast antibody with graft destruction may be explainable in
terms of selective expression of certain alloantigens on fibro-
blasts. Studies with mouse fibroblasts indicated that fibroblasts
may express both major and nonmajor histocompatibility anti-
gens, including certain nonmajor antigens with strong renal ex-
pression, but do not express Ia (DR) antigens. Since the anti-Ia
response may often not lead to graft destruction, the lack of
these antigens on fibroblasts may be an advantage when mon-
itoring destructive antibody responses. In summary, the results
suggest that antibody is associated with and may participate in
renal allograft rejection; and that fibroblast target cells may be
useful in clinical monitoring of the antibody response.
Clinicopathologic correlations in experimental membranous (M)
glomerulonephritis (GN). D. C. Cattran, and D. Man. University
of Toronto, Women's College Hospital, Toronto, Ontario. Im-
mune complex (IC) GN was induced in Wistar rats by a single
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injection of renal tubular epithelial antigen (RTE), and the rats
were followed over 14 months. Correlations were made between
circulating anti-RTE antibody (Ab), circulating antigen (Ag),
amount of IC on periodic renal biopsies, studied by immuno-
fluorescence (IF) and electron microscopy (EM), and clinical dis-
ease with proteinuria> 15 mg/day (P). Specificity of biopsy IC
was checked by elution studies using 0.02 M citrate buffer (pH,
3.2) and counterstained with specific anti-RTE raised in rabbits
and labeled with fluorescein. Controls (12 rats) were given com-
plete Freunds adjuvent (CFA) alone. Group 1(12) was given 3 mg
RTE/CFA, group 11(12) 6 mg RTE/CFA, with P appearance
being the only apparent Ag dose variation (II at 6 weeks, I at 9
weeks). No free Ag was found after 16 weeks (sera tested by
immunodiffusion against rabbit anti-RTE). All rats developed
anti-RTE within 12 weeks, varying from a titer of 1/4 to 1/32 by
indirect IF. Ab titer was independent of Ag dose. In 16 rats with
high Ab (> 1:16), P was persistent and 3/16 died. In 8 rats with
low Ab (< 1:6), P was variable. Biopsies showed less intense
glomerular granular IC by IF and moth eaten deposits on EM in
low Ab group, both suggestive of resolving complexes. Variation
in clinical outcome parallels human MGN. This study suggests
that low Ab responders are unable to initiate or propagate dis-
ease as well as high Ab group. The low Ab rat may reflect un-
known individual genetic or other host factors which are as im-
portant as Ag-type and dose in disease production.
IgA nephropathy: A prospective clinical pathologic (CP) study.
D. C. Cattran, S. Ritchie, R. Charoon, M. Johnson, and C. Car-
della, and P. Rance. Glomerulonephritis (GN) Study Group,
University of Toronto, Toronto, Ontario. In 1200 cases in the GN
registry, 7% with primary GN have predominent mesangial IgA
deposits. Forty-eight cases with > 2 year follow-up are rere-
ported here (male/female ratio, 30:18; age range, 6-75; mean, 30
years). Orientals made up 20% (10 x population %). Thirty-five
percent had macroscopic hematuria, and 60% had micro-
hematuria at presentation. Eighty percent had one or the other
during follow-up examinations. CP analysis suggests two groups.
Fluorescent and electron microscopy had no distinguishing fea-
tures, but group (G) 11(18/48 patients) versus G I (30/48) had
more sclerosis (S), interstitial fibrosis (IF), and tubular atrophy
(TA). The table shows laboratory data regarding renal in-
sufficiency as defined by creatinine (Cr) > 1.4 mg/lOO ml and/or
proteinuria (P) > 2 g/day in G I and G II at time of biopsy.
P>2g Cr>l.4mg/lOOml
(16/48) (11/48)
Group I 7/30 3/30
Groupll 9/18 8/18
At follow-up, 2 to 8 years (mean, 3 years):
Group I P 4/7 Cr no change (N/C)
Group II P 2/9 7/9 1 or N/C Cr 4/8 1
Hypertension developed in 3/18, all in Group II. This suggests all
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IgA nephropathy is not benign. Chronic slow progress occurs in
some and may be indicated by S. IF, or TA on initial biopsy.
Urolithiasis in Newfoundland: Epidemiologic and clinical fea-
tures. D. Churchill, C. Maloney, D. Black, G. Fodor, and M. H.
Gault. Faculty of Medicine, Memorial University of New-
foundland. Eighty-five percent of the total adult population
(1485) of 7 villages in rural Nfid. responded to a urolithiasis ques-
tionnaire. The urolithiasis prevalence was 8.6% (males, 9.6%;
females, 7.5%). This ranged from 2.1 to 13.2% in the 7 commu-
nities, but there was no significant correlation with drinking wa-
ter hardness (range 5 to 21 ppm) or with the concentration of Ca,
Mg, Mn, Fe, Cu, Zn, or Cd in the drinking water. The prevalence
in Protestants was 10.3% and for Catholics 5.8% (P (ye) < 0.01).
There were 34 multiple stone formers (F), of whom 26 were stud-
ied. There were 16 males and 10 females. There were 15 control
subjects (C). No subjects had hypercalcemia; 1/22 F had hyper-
uricemia; 13/30 F and 0/12 C excreted more than 150 mg calcium!
g creatinine on a free diet; mild hyperoxaluna (> 50 mg/24 hour)
was present in 3/20 F and 1/12 C. The 24-hour excretions of Mg,
Si, Mn, and Zn (in mg) are shown in the table.
Mg Si Mn Zn
F 77 30 8.4 5.5 0.48 0.68 0.75 0.29
C 85 27 7.9 5.5 0,24 0.16 0.63 0.31
P > 0.10 > 0.10 > 0.10 > 0.10
The Mg/Ca ratio for F was 0.40 (hypercalciurics 0.26; normocal-
ciurics 0.54) and for C, 0.54. This high prevalence of urolithiasis
occurs in an area with soft water and the multiple stone formers
have a 65% incidence of hypercalciuria. A low urine magnesium
occurs in both F and C. The urinary Mn, Zn, and Si excretion is
not different for F and C.
Urolithiasis (U): Environmental and genetic factors. D. N.
Churchill, C. M. Maloney, G. Fodor, and M. H. Gault. Faculty
of Medicine, Memorial University of Newfoundland, Canada. A
study of U prevalence and the relative contribution of genetic
factors and drinking water was completed in six districts in New-
foundland. One hundred and twenty stone formers (F) were iden-
tified in the random sample of 1112 adults interviewed. The male
prevalence was 15.7% (2.3 to 28.6%); females 8.3% (3.7 to
11.7%). The mean drinking water hardness was 39 ppm CaCO3
(7 to 89 ppm). Neither mean drinking water hardness, copper,
zinc, iron, silicate, sodium, magnesium, nor manganese concen-
trations in drinking water showed significant correlation with
prevalence. The U prevalence (%) in first degree relatives of F
and nonformers (NF) is shown in the table.
Parents Siblings Offspring
Father Mother Brother Sister Son Daughter
17.1 12.0 6.0 6.3 5.9 6.1
For F there was a positive family history in at least one first
degree relative in 39%; for NF, 20%. The heritability (h2) accord-
ing to the method of Falconer = 0.42. The range of drinking wa-
ter hardness was too small to demonstrate an environmental ef-
fect, but the high prevalence in soft water areas is consistent with
reports from North American and Britain. A major genetic factor
is suggested by the familial incidence.
Early detection and treatment of renal osteodystrophy. P. E.
Cordy. Department of Medicine, St. Joseph's Hospital and the
University of Western Ontario, London, Canada. To expand on
a previous study demonstrating the effectiveness of dihydrota-
chysterol (DHT) in the treatment of renal osteodystrophy (ROD)
and to detect and treat bone disease at an early stage, we carried
out biochemical, radiologic, and quantitative bone histologic
studies on 30 of the 33 patients starting hemodialysis (HD) over a
4-year period. Fifteen patients were found to have histologic evi-
dence of moderate to severe bone disease: osteoid surface (OS)
> 50%, resorptive surface (RS) > 40%. Only 8 of these had clini-
cal evidence of ROD (elevated alkaline phosphatase (AP) radio-
logic changes). Fourteen patients were treated with DHT and all
10 available for study 1 year later were submitted to a repeat
biopsy. In this latter group, together with the previously reported
6 patients with moderate to severe ROD (N = 16), the OS de-
creased from 68.8% to 42.9% (P <0.001) and the RS from 45.4%
to 19.9% (P <0.01). The mean bone area remained unchanged.
The mean combined cortical thickness of the second metacarpal
also remained unchanged. The AP decreased significantly in all
patients in whom it was originally elevated. No new fractures
and no symptoms of bone disease have developed. Mild transient
hypercalcemia occurred in 6 patients, but there was no evidence
of metastatic calcification. The group with no or mild bone dis-
ease initially was not treated with DHT, and only one has shown
clinical evidence of progression. Histologic evidence of moder-
ate to severe ROD can be detected in approximately half of pa-
tients starting HD. The majority can be treated, thus preventing
the progression to more severe, symptomatic bone disease.
Chemical amplification and reversal of tubular kidney cysts.
J. F. S. Crocker, D. A. Taylor, and C. E. Reynolds. Departments
of Pediatrics and Pathology, Daihousie University, Halifax,
Canada. Glucocorticoids are stated to have three binding sites in
the renal tubule. One of these sites is shared with the site for
aldosterone. Only certain glucocorticoids are capable of causing
polycystic kidney disease in the newborn rat and rabbit. The in-
duction of polycystic kidney disease in the newborn rat was stud-
ied with prednisolone tertiary butyl acetate and hydrocortisone
acetate. The disease was accompanied by uremia, but hypoka-
lemia was not a consistent or necessary event. Cystic formation
was amplified by specific tubular toxins such as lithium and bro-
mide but not by lanthanum, ethacrynic acid, and furosemide. Po-
tassium chloride was capable of preventing cyst formation if giv-
en daily after the steroid was injected, but this occurred only
with PTBA-induced disease, and electron microscopy of the
cysts differed significantly from those which occur in association
with hypokalemia. There was a dose-response relationship be-
tween administered steroid and cyst formation to a maximum
dose, above which cyst formation could no longer be amplified
except with the addition of certain tubular toxins. The phenome-
non of cyst formation is most likely related to physicochemical
alteration of receptor sites by the teratogenic steroid and (1)
sharing by glucocorticoid of the receptor site with a transport
site, (2) alteration by glucocorticoid of ionic transport at this site,
thereby increasing luminal pressure in the tubule and, (3) altera-
tion of luminal cell metabolism by glucocorticoid so as to in-
crease the mitotic index.
F
NF
F/NF
6 4 4 4 3 1 3.1 4.1 3.1 Donor-specific suppressor cells in human renal allografts. J. B.
27 27 19 2 0 1 4 2 0 Dossetor, E. M. Liburd, T. Kovithavongs, M. R. Higgins, and V.Pazderka Clinical and Transplant Immumology Group, Depart-
ments of Medicine and Laboratory of Medicine, University of
Alberta, Edmonton. The low requirement for immunosup-
pressive medication after the first few months following renal
transplantation suggests that donor (D) specific immunologic tol-
erance occurs, facilitated by exposure to D antigen and high im-
munosuppression during those first few months. We have sought
evidence of this by two in vitro paramaters in sequential post-
transplant sampling of recipient (R) peripheral blood lympho-
cytes (PBL): (a) changes in the capacity of mitomycin-treated D
cells (Dm) to induce cytotoxic lymphocytes (CTL) in R cells in a
6-day mixed leukocyte culture (MLC) when tested in a sub-
sequent 16-hr 51-chromium release assay for cell-mediated lym-
pholysis (CML); and (b) changes in CTL generated by Dm in
third party normal cells (X, Y, or Z) when small numbers of Rm
cells are added to 6-day MLC, as later also tested in CML against
PHA-treated 51-chromium labeled targets. These two tests were
designed to pick up donor-specific reduction of R responsiveness
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and, also, donor specific suppressor cells (SL) in R.PBL. Clear
evidence of SL was obtained in all patients (5 Cl) and 3 LD)
studied so far. SL appeared within 3 weeks and remained there-
after. No major rejections occurred in these 8 so we cannot say if
SL, and donor-specific R unresponsiveness, disappear before re-
jection. Only T cells from R.PBL subpopulations mediate sup-
pression. SL develop in HLA-identical sibling recipients after
transplant, so HLA differences are not responsible for genera-
tion of SL, in these. These data support the initial postulation,
above.
Glomerulotubular balance for bicarbonate reabsorption during
carbonic anhydrase inhibition in the dog. M. A. Duran, A. Gou-
goux, G. Lemieux, and P. Vinay. Renal Laboratory, Hôtel-Dieu
Hospital and Department of Medicine, University of Montreal,
Montreal, Quebec. While carbonic anhydrase (CA) was kept
maximally inhibited by the infusion of 20 mg/kg/hour of aceta-
zolamide, tubular reabsorption of bicarbonate was studied in
normal dogs during acute reduction of glomerular filtration by
unilateral clamping of the left renal artery. In 16 dogs given 5%
mannitol alone, a striking proportionality (r = 0.973) was main-
tained between the amount of filtered and reabsorbed bicarbo-
nate (glomerulotubular balance). Glomerular filtration in the left
kidney was reduced to values ranging from 99% to 5% of control.
In 10 other dogs loaded with sodium bicarbonate (plasma bi-
carbonate, 35-40 mM/liter), a direct relationship (r = 0.946) was
also observed between filtered and reabsorbed bicarbonate. In
these experiments glomerular filtration of the clamped kidney
was reduced to values ranging from 96% to 3% of control. Distal
blockade with ethacrynic acid and chlorothiazide, performed in 5
dogs with normal acid-base balance and in 5 sodium bicarbonate-
loaded dogs, does not abolish glomerulotubular balance for bi-
carbonate reabsorption during CA inhibition. The present study
demonstrates that glomerulotubular balance for bicarbonate is
maintained during CA inhibition. Since changes in bicarbonate
and sodium reabsorption were closely related in all experiments,
decreased passive back flux of sodium and bicarbonate from
proximal peritubular fluid to tubular lumen could explain the
maintenance of this glomerulotubular balance.
Loading dose of digoxin in renal failurç. M. H. Gault, J. Kalra,
and D. Churchill. Faculty of Medicine, Memorial University of
Newfoundland, Canada. Controversy exists about the loading
dose of digoxin in renal failure, with suggestions ranging from
use of the same dose as is given for patients with normal renal
function, to half that dose. The average apparent volume of dis-
tribution (VD) of digoxin in advanced renal failure (creatinine
clearance < 9)has been reported in 5 studies to average 362 liters(N = 23), compared with 548 liters for those with normal renal
function (N = 22). We report serum digoxin concentrations
(SDC) by radioimmunoassay taken during the 24 hours after 20
to 30 mm's i.v. infusion of 10 j.g!kg digoxin in 22 patients (6
female) with acute (N = 4) or dialysis-dependent chronic renal
failure (N = 18). Ages ranged from 20 to 82 years. The mean
values for SDC so were at 15 mm, 11.1 3.1 (N = 9); 30 mm,
8.2 2.6(N = 11); 2hr, 3.4 0.9(N = 9); 8 hr, 1.7 0.6(N =
15); and at 24 hr, 1.5 0.4ng/ml (range, 0.8 to 2.1, N = 22). No
evidence of toxicity was observed. There were no significant dif-
ferences between mean values for M and F or for those with
acute and chronic renal failure (P > 0.1). The mean VD for the
group was 440 liters or 6.7 liters/kg, calculated from SDC values
at 24 hrs. The mean t'/2 calculated from mean 8- and 24-hour
values was 86 hours, and the mean VD determined by back plot-
ting to obtain zero time concentration was 370 liters or 5.6 liters!
kg. No significant correlation (P = > 0.1) was found between the
VD calculated as liter or liters/kg at 8 or 24 hours with age, or
concentrations of serum creatinine, sodium, potassium, or chlo-
ride. We have confirmed that there is a reduction in the VD of
digoxin in advanced renal failure and recommend an i.v. loading
dose of7to l0g/kg.
Relationship of mtra major histocompatibility complex dif-
ferences to cardiac allograft rejection and prolongation in the rat.
R. D. Guttmann, R. D. C. Forbes, D. V. Cramer, and T. J. Gill,
III. Royal Victoria Hospital and McGill University, Montréal,
Québec, and University of Pittsburgh School of Medicine, Pitts-
burgh, Pennsylvania. The effect of rat major histocompatibility
complex SD and LD antigen differences on the pathogenesis of
rejection of cardiac allogralts has been studied using three mod-
els: acute rejection, hyperacute rejection, and prolongation by
active immunization with bone marrow cells. The strains used
share the MLR and La loci (B region) and are unresponsive in in
vitro culture; however, they differ at the A region which deter-
mines SD antigens, and strong cytotoxic antibody responses are
seen after immunization. It was found that under conditions of
no sensitization, cardiac allografts reject acutely in 9 days
(range, 7 to 14) and under conditions of skin graft immunization,
in spite of negative MLC responses, hyperacute rejection (< I
day) is seen associated with high cytotoxic antibody titers. At-
tempts at active enhancement were made using a standard pro-
tocol known to increase survival in other strain combinations,
and grafts were rejected in 13.4 days (range, 5 to 24 days), thus
prolongation of graft survival was not impressive. This study
clearly demonstrates that in spite of MLR and Ia antigen match-
ing, sensitization for SD antigens results in humoral rejection.
The experiments also show results compatible with previous ob-
servations, suggesting that a poor in vitro MLC proliferative re-
sponse in unsensitized recipients of certain strain combinations
is associated with the inability to achieve striking enhancement
when the active immunization protocol is used.
Renal osteodystrophy in childhood: An unexpectedly common
complication of chronic renal failure. A. C. Hsu, S. W. Kooh, W.
A. Cumming, G. S. Arbus, V. L. Fornasier, and D. Fraser. De-
partment ofPaediatrics, Radiology and Pathology, University of
Toronto and Research Institute, The Hospital for Sick Children,
Toronto, Canada. Fifty newly diagnosed children with chronic
renal failure were studied repeatedly for 1 to 7 years as renal
insufficiency progressed. Sixty-eight percent (34 patients) devel-
oped radiographic evidence of renal osteodystrophy (rickets and!
or hyperparathyroid changes) before dialysis or transplantation
was required. In addition, four patients without radiographic evi-
dence of osteodystrophy had lesions on histologic examination.
One quarter of the patients developed noticeable skeletal defor-
mities. In most of the patients with osteodystrophy, the radio-
graphic lesions of rickets and hyperparathyroidism developed
within 2 years of the appearance of chronic renal failure, usually
while serum creatinine was still < 3 mg/dl. The rachitic com-
ponent of renal osteodystrophy improved initially with therapy
including large doses of vitamin D, but the hyperparathyroid le-
sions responded poorly. This study shows that the incidence of
renal osteodystrophy is much greater in children than is general-
ly realized and that debilitating bone lesions are particularly
prone to occur in infants, often before renal function has become
seriously impaired.
Failure of immunosuppression with cyclophosphamide (CY),
aathioprine (AZ), and prednisone (P) to improve cadaveric allo-
graft survival. J. R. Jeffery, A. R. Downs, C. Lye, E. Ramsey,
and A. E. Thomson. Transplant Program, Health Sciences
Centre and University of Manitoba, Winnipeg, Canada. To as-
sess the effectiveness of immunosuppression with cyclophospha-
mide, we randomized 33 patients into treatment with CY (400 mg
iv.) on days 0, 3, 6, 14, 21 posttransplant and for rejection epi-
sodes, and with AZ (1.5 to 2 mg/kg/day) except on CY days
(group A); and 28 patients into treatment with AZ (2 to 3 mg/kg!
day) (group B). Both groups were given P (100 mg/day tapering
to 50 mg/day by day 28 and 15 mg/day by 1 year) and methyl-
prednisolone infusions (1 g) on days 0, 3,6, 14, 21, and for rejec-
tion episodes. All patients have been followed for at least 6
months.
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Antigens matched
No. transfusions
Pt, survival5 @ 3 mo, %
Pt. survival @ 12 mo, %
Graft survival @ 3 mo, %
Graft survival @ 12 mo, %
Group Group
A(33)a B(28)5
1.4 1.3
16 16
97.0 96.4
97.0 87.0
66.7 71.4
66.7 63.9
a None of the results are significantly different.
Life-table analysis.
There was no difference in infectious complications between the
two groups. These results demonstrate neither beneficial nor
harmful effects from the additional use of cyclophosphamide.
Circulating immune complexes in patients with idiopathic forms
of glomerulonephritis. K. V. .Johny, M. Dasgupta, B. Singh, and
J. B. Dossetor. Clinical and Transplant Immunology Group, De-
partments of Medicine and Laboratory Medicine and Immunolo-
gy, University of Alberta, Edmonton, Canada. Circulating im-
mune complexes (CIC) are reported in many immunopathogenic
states, as well as in normal pregnancy. Their role is not defined
because (a) of paucity of data correlating sequential testing with
changing clinical events, and (b) no single test may give a com-
plete picture of CIC even in individual patients. CIC are precipi-
tated by 3.5% polyethylene glycol (PEG); PEG precipitant
(PEGP) is then dissolved for quantitation. We are also using oth-
er CIC systems: cultured Raji cells; complement (Clq) binding;
bovine conglutinin binding; and inhibition of effector cells in an
antibody-mediated cellular cytotoxicity (ADCC). Raised PEGP
levels were found in 8 of 24 (33%) patients with idiopathic gb-
merulonephritis (membranous, membranoproliferative, mesangi-
at, and focal) in contrast to 5% in normals. Activity of renal dis-
ease was clinically assessed. High levels of PEGP occurred in 6
of 12(50%) patients with active disease, but only in 2 of 12 (17%)
where disease activity was low. Sequential monitoring of 8 pa-
tients showed decreasing levels of PEGP in those with clinical
improvement, occurring in association with immunosuppressive
treatment in some; in those with no improvement, PEGP re-
mained unchanged. Correlation between PEGP and Raji meth-
ods was not good, emphasizing the merit of a spectrum of tests in
this form of immunologic monitoring.
Hematologic state of patients undergoing continuous ambulatory
peritoneal dialysis (CAPD). A. Katirtzoglou, D. G. Oreopoulos,
N. Dombros, A. Pierratos, and D. Pantalony. Toronto Western
Hospital, and University of Toronto, Toronto, Canada, Hemato-
logic observations were performed on 38 patients (15 men and 23
women) undergoing CAPD for 3 to 10 months (average, 6
months). All received I tablet of a multivitamin preparation dai-
ly, containing small amounts of iron. Serial monthly measure-
ments of hemoglobin (Hb) showed a significant gradual increase
in most of them, with the mean value increasing from 7.6 g/dl
before to 10.7 g/dl after 10 months on CAPD. Over the same
period the mean hematocnt increased from 23 to 31%. Ten pa-
tients (26%) had Hb levels above 11 gldl, five (13%) above 12 g/
dl, and four (10%) above 13 g/dl. In a cross-section study of the
serum iron ferritin, folates, and vitamin B12 levels, we obtained
the following results.
CAPD
patients
(± so)
101 51
252 57
41 21
277 246
13.5 6.5
1116
870 239
These findings indicate that CAPD over a period of up to 10
months does not remove any of the above substances in signifi-
cant amounts. Better control of the "uremic state" by CAPD
seems to be the underlying mechanism for the dramatic improve-
ment in the hemoglobin level of these patients.
Poststreptococcal glomerulonephritis (PSGN): Long-term follow
up. J. Lien, T. H. Mathew, and R. Meadows. Renal Unit and
Histopathology Department, The Queen Elizabeth Hospital,
Adelaide, Australia. The long-term outcome after acute PSGN
was studied in 57 patients (pts), 52 aged 16 or over, who were
followed up for a period of I to 14 (mean, 7) years. All cases
presented with features of acute nephntis: hypertension, hema-
tuna, and proteinuria. ASOT was raised, or the serum com-
plement was low in all at the initial episode. All had histologic
evidence of a diffuse proliferative and exudative glomerulone-
phritis at onset. Follow-up renal biopsies were performed in 33
pts; in 18, these were performed 5 years or more after the initial
illness. Five pts died after 2 years, two with abnormal renal func-
tion at the time of death. At follow up, 4 were mildly hyperten-
sive without other clinical abnormalities. Eleven pts had protein-
uria, hematuria, or abnormal renal function. Of these 11 pts, re-
peat renal biopsies were normal in 3, incomplete resolution was
found in 5, sclerosed glomeruli were present in I, and 2 others
were not biopsied. Sclerosed glomeruli were present in 2 addi-
tional cases at follow up with evidence of incomplete resolution.
All 7 repeat biopsies performed after 9 years of follow up were
normal. No patient who had normal renal function clinically at
the time of follow up had abnormal renal histology on biopsy. It
was concluded that the majority of pts with acute PSGN have a
good long-term prognosis. Complete histologic resolution of the
renal lesion may not occur for up to 9 years. Pts with minor clini-
cal renal dysfunction at the time of follow up may have either no
histologic change of significance or evidence of incomplete heal-
ing with or without the presence of sclerosed glomeruli.
D1-2-ethylhexyl phthalate (DEIIP) accumulation in dialyzed
uremic patients. M. A. Mishkel, D. J. Nazir, and A. G. Shimizu.
Departments of Medicine & Clin. Chemistry, McMaster Univer-
sity, Hamilton, Ontario. Phthalates, largely DEHP, are being
used in increasing amounts in biomedical equipment. Concerns
have been expressed that prolonged exposure to phthalates may
result in subtle toxicity to living organisms. The dialyzed uremic
patient is particularly prone to accumulation of DEHP because
of the frequent and prolonged recirculation of his blood volume
through plastic tubing. Two other factors increase exposure and
accumulation of DEHP in the patient: the main route of its excre-
tion through the kidney is lost; hyperlipemic plasma (a common
finding in dialyzed patients) increases the tendency to leach
DEHP from the tubing. The finding of significant accumulation of
DEHP in autopsy tissue is presented in 7 patients, 6 on long-term
dialysis and 1 who received massive blood transfusions; tissues
from 4 controls were similarly analyzed. Adipose tissue con-
tained most of the DEHP due to the relatively high concentration
of DEHP (up to 460 sg/g tissue) and to the high total weight of
this tissue. Bone marrow, brain, and peripheral nerve all showed
moderate accumulation (up to 100 g/g tissue), and lesser
amounts were also seen in the kidney, liver, lymph nodes,
spleen, lung, and heart. Of 4 controls, 3 showed much less tissue
accumulation of DEHP: 1 control showed considerable accumu-
lation of DEHP in adipose tissue. There is growing evidence not
only for the accumulation of DEHP in tissues but also for its
effect on intracellular enzymatic systems. This has potential rele-
vance for the dialyzed uremic patient.
Use of computerized tomography (CT) to evaluate bleeding after
renal biopsy. P. A. Morrin, J. G. Ginsburg, S. L. Fransman, M.
Cohanim, and M. A. Singer. Queen's University, Departments
of Medicine and Radiology, Kingston General Hospital, Kings-
ton, Ontario, Canada. We used CT scanning to evaluate bleed-
Iron, g/dl
Iron bind, cap, pg/dl
Saturation, %
Ferritin, ng/ml
Serum folates, ng/ml
RBC folates, ng/ml
Vitamin 12pg/mi
Normal
7Oto 180
250 to 400
24to 49
lOto 300
4to 16
l6Oto 700
200to 1100
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ing following percutaneous renal biopsy in 18 patients. A General
Electric whole body scanner using a fan beam and a xenon gas
chamber detection system was used. The exposure time per slice
was 4.8 seconds and the slice thickness was 10 mm. Prior to
biopsy, the platelet count, PT, PTT, bleeding time, and clotting
time were all normal. A modified Vim Silverman biopsy needle
was used, and 2 samples were taken in most cases. Image in-
tensification following injection of contrast medium was used for
renal localization in 17 cases and ultrasound in 1. In 8 cases no
significant abnormality was present. Subcapsular hematomas
were found in 10; they were small in 6, moderate in 2, and large
in 2. A small intrarenal hematoma was present in I patient who
also had a moderate subcapsular hematoma. Only the patients
with large hematomas had significant clinical and laboratory ab-
normalities. Unsuspected renal cysts were identified in 3 pa-
tients. A repeat scan after 6 weeks in a patient with a large hema-
toma showed almost complete resolution. It is concluded that the
magnitude of postbiopsy renal bleeding is underestimated by
clinical assessment and hemoglobin measurements.
Platelet hyporesponsiveness to epinephrine in carriers of Bart-
ter's syndrome. S. O'Regan, G. E. Rivard, and P. Robitaille.
Department of Pediatrics (Nephrology and Hematology),
Hópital Ste-Justine, Institut de Recherches Pédiatriques, Uni-
versité de Montréal, Montréal, Québec, Canada. Previous stud-
ies have demonstrated gross platelet hypoaggregability to epi-
nephrine collagen and ADP in patients with Bartter's syndrome.
Platelet aggration was performed utilizing Ristocetin, ADP (6 x
10-6 M), collagen (COLL) (1 pg/mI), and epinephnne (EPI) (6 x
10-6 M and 2 x 10-6 M) on platelets from light obligatory hetero-
zygotes, i.e., the parents of 4 patients with Bartter's syndrome.
All subjects demonstrated normal aggregometry responses to
Ristocetin and ADP with variable responses to COLL at the con-
centrations used. Seven of the eight subjects had marked platelet
hypoaggregability in response to EPI, 6 x 10-6 at. One subject
failed to aggregate at a concentration of 2 x 10_6 at, a concentra-
tion at which control platelets from normal subject aggregated
normally. The maximal percent of light extinction attained due to
platelet aggregation (1 = father, 2 = mother) was:
2
8Oto 100 8Oto 100
These studies indicate that platelet aggregation in response to
EPI (2 x l0s) can be used for identifying Bartter's syndrome
carriers.
Kinetics of preformed immune complexes infused into rats with
Heymann's nephritis. S. O'Regan and M. Smith. Department of
Pediatrics, Nephrology, Hôpital Ste-Justine, Institut de Rech-
erches, Pédiatriques, Université de Montréal, Montréal,
Quebec, Canada. Previous studies have suggested that retic-
uloendothelial system (RES) suppression with possible failure
of normal clearance of circulating immune complexes may be
responsible for the evolution of immune complex glomerulone-
phritis. Twelve Lewis strain rats were infused with proximal
tubular antigen in complete Freund's adjuvant to induce mem-
branous nephropathy (Heymann's nephritis). Ten animals of the
same strain served as controls. Three months after serial injec-
tion with antigen the presence of nephrosis was confirmed by
gross proteinuria, hypoalbuminemia, and hypercholesterolemia.
Rats were infused by tail vein with '251-labeled preformed im-
mune complexes, the antibody being radiolabeled, the com-
plexes being solubilized at 30 times antigen excess. Serial blood
samples were obtained at 5 mm, 30 mm, I hr, 2 hrs, 3 hrs, 4 hrs, 5
hrs, and 24 hrs, and the animals then were sacrificed. Kidney,
liver, and spleen were obtained for assessment of total uptake.
The clearance of preformed immune complexes were not signifi-
cantly different between experiment and control groups of ani-
mals for 3 hours. Thereafter, there was a significantly increased
clearance from the systemic circulation in experimental animals.
There was a significantly increased uptake by the spleen in ex-
perimental animals. Also renal uptake was increased, suggesting
that the presence of proteinuria might have allowed for some
trapping of complexes. These studies indicate that the ability of
the RES to clear complexes in this form of glomerular disease is
augmented.
First year's experience with continuous ambulatory peritoneal
dialysis (CAPD). D. G. Oreopoulos, M. Robson, N. Dombros,
and A. Pierratos. Toronto Western Hospital, Toronto, Ontario,
Canada. With the technique we have described (ASAIO, 1978),
CAPD has become a simple and relatively safe procedure. Using
this technique, we have trained 56 patients, 24 men and 32 wom-
en, during the past year. Their ages varied from 11 to 75 years
(mean age, 49 years). Of these, 43 were on intermittent PD for 3
to 54 months before they were started on CAPD, and the remain-
ing 13 were new patients. The mean period on CAPD was 4.4
months. In the new patients, the average training period was 10
dialysis days. Most pts (47) exchange 2 liters of dialysate 4 times
a day 7 days a week. Those pts (9) who on the above schedule
had a serum creat. < 10 mg/lOO ml continued doing well when
switched to 3 exchanges a day. The average (±sD) biochemic
and hematologic values at the time of this report are: serum
creat., 12.1 3.3 mg; BUN, 59 19mg; calcium, 9.1 0.9mg;
phosphorus 4.8 1.5 mgA; albumin, 3.3 0.5 g/lOO mg., Tot.
prot. 6.4 0.6/100mg, Hb 9.0 1.9/100mg. To control ser. P41
pts required small doses of AL(OH)3. Only 12 pts required anti-
hypertensive medications. All pts enjoyed their "life without a
machine" and absence of dietary and fluid restrictions. Thirty-
five episodes of peritonitis occurred among 22 pts, an incidence
of one episode every 7.05 patient months. Seventy-one percent
of the episodes were due to gram-positive organisms, 17% to
gram-negative, 6% to fungi, and 6% were aseptic. Five pts re-
ceived a kidney transplant, 5 were transferred to in-center PD, 3
to hemodialysis, I died, and 42 are still on CAPD. Our experi-
ence to date indicates that with the use of our technique, CAPD
is a simple, safe, and successful dialysis method which will have
a great impact in the treatment of end-stage renal disease.
Effect of 1,25(OH)rvitamin D3 on renal osteodystrophy. A.
Pierratos, D. G. Oreopoulos, S. Rabinovich, H. E. Meema, H.
Meindok, T. Murray, H. Husdan, H. Harrison, and A. Katirt-
zoglou. Toronto Western and St. Michael's Hospitals, and De-
partment of Medicine, University of Toronto, Toronto. Eight pa-
tients with severe renal osteodystrophy (seven on dialysis and
one nondialyzed) were treated with 1 ,25(OH)2-vit. D3 (0.1 to 1
pg/day) for periods of 6 to 15 months. Hyperparathyroidism
(HP'F) was the predominant abnormality in 3, osteomalacia (OM)
in 3, and the remainder had mixed lesions. Serum Ca, P, and alk.
phosph. were measured biweekly. Plasma iPTH, intestinal 45Ca
absorption x-ray of hands, bone scan, and bone biopsy were per-
formed before and after 6 months of treatment. Hypercalcemia,
rapidly responding to a decrease in the dose of the drug, oc-
curred frequently. Relief from bone pain, a decrease in iPTH and
alk. phosph., and histologic and radiologic improvements were
observed in those patients with predominant HPT. On the con-
trary, those patients with predominant OM lesions had a poor
response after 6 months of treatment. In one of these patients,
healing of rib fractures was observed after 1 year's treatment. Of
the two patients with mixed lesions, one showed no response and
Family
A'
A2
B'
B2
C'
C2
D'
D2
D2
Control
ADP,6 x I0at
97.1
92.8
84.3
97.1
94.3
82.9
91.4
92.8
COLL,
lpg/ml
10.1
100.0
5.7
18.1
18.6
62.9
90.0
92.8
x I0at
EPI,6 x l0ai
30.0
22.8
27.1
42.8
20.0
9.6
2.8
90.0
8.5
80to 100
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the other showed improvement in the osteitis component of his
disease. A drug-related deterioration of renal function was ob-
served in the nondialyzed patient, while on treatment. Our re-
sults indicate that treatment with 1 ,25(OH)2-vit. D3 for 6 months
is effective in controlling secondary HPT but not OM. In patients
with the latter complication, a longer period of.treatment may be
beneficial. In nondialyzed patients, treatment with 1 ,25(OH)2-
vit. D3 may result in a further deterioration of renal function.
Pathogenesis of acidosis and hypokalemia in hereditary fructose
intolerance (HF!). R. M. A. Richardson, J. A. Little, R. L. Pat-
ten, M. B. Goldstein. and M. L. Ha/penn. Departments of Medi-
cine and Clinical Biochemistry, St. Michael's Hospital, Toronto,
Ontario, Canada. A 20-year-old man with a classic history of
HFI developed the typical biochemical changes within 2 hours
after a 20-g oral fructose load: fructosemia (14 mg/dl), hypogly-
cemia (22 mgldi), metabolic acidosis (pH, 7.24; HCO3, 17 mEq/
liter), hypophosphatemia (1.9 mg/dl), hypokalemia (3.1 niEqlli-
ter), and hyperuricemia (8.3 mg/dl). Possible causes for the meta-
bolic acidosis were analyzed. Proximal renal tubular acidosis
(pRTA) was present as the urine pH at 3 hours was 7.6 and HCO3
reabsorption per liter GFR fell from 24 to 18 mEq/liter. How-
ever, the fractional excretion of HCO3 was only 7.5%, less than
the 15% expected in pRTA, indicating additional causes for the
metabolic acidosis. The urine minus blood Pco2 gradient (U-B
Pco2) was high (80 mm Hg), ruling out distal RTA of the secre-
tory-limit type. Studies in other patients with HFI showed a min-
imum urine pH < 5.3 with acidemia, ruling out distal RTA of
the back-diffusion type. The other type of acidosis present was
lactic acidosis (anion gap, 23 mEq/liter; blood lactate, 5 mEqili-
ter). Other renal tubular defects noted in addition to pRTA were
renal uricosuria, proteinuria, lactaturia, and phosphaturia. The
hypokalemia was not explained by urine K loss and reflected
either K entry into cells with phosphate or G.l. K sequestra-
tion. Thus, acidosis in HFI is due to pRTA and lactic acidosis,
whereas distal RTA is not present. All defects were rapidly re-
versible on a fructose-free diet.
Effects of mineralocorticoids and potassium on collecting duct
hydrogen ion secretion (CDHS) in the rabbit W. L. M. Robson,
R. M. A. Richardson, M. G. GOldstein, B. J. Stinebaugh, andM.
L. Halperin, Department of Medicine, University of Toronto,
Toronto, Ontario, and Baylor College of Medicine, Houston,
Texas. CDHS was evaluated by measuringthe urine minus blood
Pco2 gradient in alkaline urine (U-B Pco2) in male New Zealand
white rabbits. In both normals and rabbits pretreated with SO tg
of 9-a-fluorohydrocortisone orally, the U-B Pco2 was measured
before and following potassium infusion. The urine bicarbonate
concentrations were similar (—150 mEq/liter) in all studies.
Normal (N = 10) Mineralocorticoid (N 9)
Plasma K U-B Pco2 Plasma K U-B Pco2.
mEqiliter mm Hg mEqiliter mm Hg
2.4 7±1 2.4 12±2
4.1 15±2 3.9 21±3
Note the low "normal" U-B Pco2 which is increased by both
acute infusion of K and by administration of mineralocorticoid.
The U-B Pco2 was also significantly elevated following a K in-
fusion into animals pretreated with mineralocorticoids. This sug-
gests that potassium may effect CDHS by a mechanism which is
independent of elevating the mineralocorticoid level. Con-
clusion. Both K and mineralocorticoid administration stimulate
CDHS in the rabbit, probably by separate mechanisms.
Glomerular hemodynamics computed from the dimensions of a
reconstructed glomerular model. S. M. Shea. Department of Pa-
thology, CMDNJ-Rutgers Medical School, Piscataway, New
Jersey. A model of a glomerulus of a Sprague-Dawley rat was
reconstructed from electron micrographs of subserial ultrathin
sections. The reconstructed glomerulus was intermediate in size
between the cortical and juxtamedullary glomeruli of the Wistar
rat. The length and diameter of each of the 320 glomerular capil-
lary segments were determined, its connections graphed, and re-
sistance calculated, with Poiseuille flow and an apparent blood
viscosity of 1.82 cP being assumed. Capillary segments were 8.28
2.68 m in diameter, 20.78 13.67 sm long, and 551.3 427.4
Aj2 in area (total length, 6.65 mm; total area, 0.176 mm2). By
assuming an efferent hematocrit of 50% and an efferent plasma
flow of 0.8485 nI/see, we computed minimum node pressures for
the resistance network and a minimum axial pressure difference
between afferent and efferent arteriole of 2.92mm Hg. Minimum
estimates of segment blood velocities and maximum estimates of
segment transit times were similarly calculated. These velocities
had a mean value of 0.122 cm/sec (so 0.160 cm/see). From
segment transit times and the graph of paths aecross the net-
work, a distribution of network transit times was derived. The
relatively large axial pressure difference calculated for the whole
network (2.92 mm Hg) corroborates studies suggesting that filtra-
tion equilibrium is attained in the Munich-Wistar rat.
Calcium oxalate inhibitory factors in urine. P. C. Singhal, H.
Mandin, A. Jacobson, and J. Hyne. Faculties of Medicine &
Science, University of Calgary, Calgary, Alberta. Previous
workers have shown various factors in urine with varying stone
inhibitory action, i.e., pyrophosphate (10%), magnesium ions
(20%), phosphocitrate (50%). However, 20% of the inhibitory ac-
tivity remains unidentified. We have used changes in the rate of
precipitation of calcium oxalate in an attempt to identify the fac-
tors in urine which may inhibit stone formation. Results are giv-
en in the table below. The major factors in urine which inhibit
calcium oxalate precipitation are bound to DEAE Sephadex A-
25 (an ion exchanger), suggesting that the inhibitory factors are
negatively charged. Only a high-salt concentration causes re-
lease from the DEAE. The fraction which caused inhibition was
both ninhydrin and phosphate positive. Two further fractions
were separated on a Biogel P-2 column. The first gave a positive
phosphate and nitrogen test. The second appeared to be a mix-
ture in the ninhydrin test and tested negative for phosphate.
No urine
Pooled urine, ml
DEAE-treated
DEAE and CM-treated
Extractions:
pH 2.5, no salt
0.6 M KCI
0.8 M KCI
l.OM KCI
Parathyroid resistance in acute renal failure caused by phos-
phate retention. P. J. Somerville and M. Kaye. Division of Ne-
phrology, Montreal General Hospital, Montreal, Canada. The
cause of resistance to the calcemic action of parathyroid hor-
mone in renal failure was determined using the following animal
model. Rats were thyroparathyroidectomized, and catheters
were inserted into the jugular vein and the bladder. Two hours
later they were injected with Lilly Parathyroid Extract (PTE), 80
pJlOO g, and urine collected over the previous 2 hours was rein-
fused during the next 30 mm. This 30-mm cycle was repeated
until the rats were killed 5 hours after the PIE. Controls were
reinfused with an electrolyte solution instead of urine. The final
plasma Cain the "uremic rats" was 12.0 0.3 mg/dl, and in the
electrolyte infused rats 14.9 0.3 mgldl (P <0.001). Two further
experiments were carried out in which each batch of urine was
either treated with activated charcoal or passed through an Ami-
con membrane (MW. cut-off 500) prior to reinfusion. In both
eases the calcemic response did not differ significantly from that
Rate constant
Conductivity
dX/dt
0.45
0.12
0.45
0.45
Ca electrode
see
50 10
22 4
44 6
44 7
55 8
45 6
16 5
36 5
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of the "uremic rats." However, when zirconium oxide, which
removes phosphate (Pi) from urine, was used instead of char-
coal, the plasma Ca was 14.5 0.4 mg/dl, not significantly dif-
ferent from the "electrolyte" infused rats. In another series of
studies, the addition of increasing amounts of Pi to the elec-
trolyte solution resulted in increasingly lower plasrria Ca values,
and a linear relationship between the plasma Ca and the Pi dose
was noted (Ca = 14.84 — 0.139 Pi). These studies show conclu-
sively that parathyroid resistance in this model is caused by
phosphate retention.
Acute effects of hydrochiorothiazide (HCZ) on urinary elec-
trolyte excretion in calcareous renal stone formers. R. A. L. Sutton
and V. R. Walker. Clinical Investigation Unit, Shaughnessy
Hospital, Vancouver, British Columbia, Canada. To identify dif-
ferences in renal tubular function between calcareous renal stone
formers and normal subjects, we have measured the urinary ex-
cretions of Na, Ca, Mg, and Pi following a single oral dose of 100
mg HCZ in 23 idiopathic calcareous stone formers and 14 age-
matched normal controls. Excretions during 4 hours following
the diuretic were compared with the same time period on the
previous day when no drug had been given. Subjects were fasting
during these studies. The mean increments in ion excretions per
milligram creatinine were:
Na,mEq Ca,mg Mg,mg Pi,mg
Patients 0.242* 0.036** 0.030* —0.014
Normals 0.183
<
0.010
0.05 **
0.012
< 0.01)
0.011
Before administration of the diuretic, mean Nalcreatinine (0.079
vs. 0.100), Mg/creatinine (0.061 vs. 0.060), and Pi/creatinine
(0.376 vs. 0.428) ratios were similar, but mean Ca/creatinine ratio
was significantly higher in stone patients than it was in normals
(0.124 vs. 0.076**). The greater increments in Na, Ca, and Mg
excretion following HCZ in stone formers are consistent with the
presence of impaired tubular reabsorption in the more proximal
nephron, which is presumably offset by increased distal Na and
Mg (but not Ca) reabsorption. Blockade of distal reabsorption by
HCZ would then result in the abnormal increments in ion excre-
tions that we have observed.
Early changes in renal metabolites profile during acute acidosis
in dogs and rats. P. Vinay, G. Lemieux, and A; Gougoux. Renal
Laboratory, Hôtel-Dieu Hospital, Department of Medicine,
University of Montreal, Montreal, Canada. Acute metabolic
acidosis was induced by i.v. HCI administration to rats and dogs
to diminish plasma bicarbonate from 26 to 10 (rats) and from 22
to 12 mM/liter (dogs). Kidney metabolite profile was determined
on freeze-clamped tissue before and after 30, 60, 120, or 240 mm
of acidosis in rat and after 60 mm in dog. In rats, kidney gluta-
mine concentration decreased from 1.5 to 1.2, glutamate from 2.8
to 1.7, and alphaketoglutarate from 0.25 to 0.12 m after 30 mm
of acidosis. Malage, oxaloacetate, and phosphoenolpyruvate
concentrations were unchanged or slightly increased by this ma-
neuver. After 60 mm, however, malate and oxaloacetate concen-
tration were significantly lowered as the phosphoenolpyruvate
concentration tended to rise. In the dog, no significant fall of
oxaloacetate or malate was observed after 60 mm or after 5 days
of chronic metabolic acidosis. In both species, the tissue citrate
concentration decreased by 50%. These data suggest that the
early fall in glutamine, glutamate, and alphaketoglutarate con-
centration in rat or dog kidney is not due to PEPCK activation
and are interpreted as an indirect evidence for alphaketoglutarate
dehydrogenase stimulation by acute (rats and dogs) or chronic
(dogs) acidosis in vivo.
Fasting urine calcium: Calcium load test in calcium nephroli.
thiasis. D. R. Wilson, G. Pylypchuk, S. Fox, A. Angel, and J.
Harrison. Department of Medicine, University of Toronto, Can-
ada. The fasting urine calcium/creatinine ratio (FUcajcr), the in-
crease in urine Ca/Cr after an oral calcium load (tiLU*icr), and
urine cyclic AMP levels (UCAMP) were measured in 75 calcium
stone formers (SF), 16 patients with primary hyper-
parathyroidism(HPT) and 10 normals (N). SF were divided into
4 groups based on normal or increased 24-hr urine calcium (U)
and normal or increased intestinal 45Ca absorption. Among SF
with 24-hr hypercalciuria, did not separate those with
hyperabsorption from those without. When 24-hr U8 was nor-
mal, FUcar was normal, and these two parameters increased to-
gether with a correlation r = 0.43, P < 0.01. xLUc,c. was also
higher in SF with hypercalciuria; SF with increased absorption
had normal or FUcaicr and also normal or 24-hr U. FUcajcr
and UCAMP were higher in HPT than other SF (resorptive from
renal or absorptive hypercalciuna, P < 0.01). The correlation of
with 24-hr Uca in SF suggests that overnight fasting does
not eliminate the absorptive contribution to and indicates
the importance of prior dietary Ca intake in the interpretation of
this test. The Ca load added little to the differential diag-
nosis of hypercalciuna in SF except in patients with possible
HPT.
